Related Experiment Video
Updated: Jan 17, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Drug and Clinical Candidate Drug Data in ChEMBL
Fiona M I Hunter1, Harris Ioannidis1, A Patrícia Bento1
1European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom.
None:
ChEMBL is a large-scale, open-access, FAIR database of bioactive molecules with drug-like properties. ChEMBL 35 contains 17,500 approved drugs, and drugs that are progressing through the clinical development pipeline. Drug curation has formed an integral part of the core offering of the ChEMBL database since its inception. The paper is a reference guide to present the principles of why the ChEMBL drug data has been curated in a particular manner so that data users can better understand the nature of the data. The drug data include information on: names, synonyms and trade names, chemical structure or biological sequence, data sources, indications, mechanisms, warnings and drug properties such as maximum phase of development, type of molecule, prodrug status and first approval. The integrated nature of the drug data within the context of a bioactivity resource enables the wide use of the data set in drug discovery, AI and machine learning.
More Related Videos
Related Concept Videos
Drug Discovery: Overview
Clinical Trials: Overview
Preclinical Development: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Biotransformation: Overview

